Inventor
IOFFE ELLA
US18 patents
⚠️ This page may combine multiple inventors who share the name “IOFFE ELLA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
REGENERON PHARMA
15 patentsUS9987500B2Jun 5, 2018
Human antibodies to PD-1
REGENERON PHARMA126 citations99
US10358495B2Jul 23, 2019
Anti-LAG3 antibodies and uses thereof
REGENERON PHARMA47 citations96
US9938345B2Apr 10, 2018
Human antibodies to PD-L1
REGENERON PHARMA37 citations94
US9968674B2May 15, 2018
Methods and compositions comprising a combination of a VEGF Trap and an anti-CTLA-4 antibody
REGENERON PHARMA10 citations84
US10737113B2Aug 11, 2020
Human antibodies to PD-1
REGENERON PHARMA2 citations73
US11692032B2Jul 4, 2023
Anti-LAG3 antibodies and uses thereof
REGENERON PHARMA3 citations72
US10939673B2Mar 9, 2021
Method of using mouse having a humanized cluster of differentiation 47 gene
REGENERON PHARMA1 citations72
US10844137B2Nov 24, 2020
Anti-CTLA-4 antibodies and uses thereof
REGENERON PHARMA2 citations72
US12389889B2Aug 19, 2025
Mouse having a humanized cluster of differentiation 47 gene
REGENERON PHARMA0 citations62
US12024570B2Jul 2, 2024
Anti-CTLA-4 antibodies and uses thereof
REGENERON PHARMA0 citations62
US11910788B2Feb 27, 2024
Mouse having a humanized cluster of differentiation 47 gene
REGENERON PHARMA0 citations62
US10015953B2Jul 10, 2018
Non-human animals having a humanized cluster of differentiation 47 gene
REGENERON PHARMA1 citations62
US12187772B2Jan 7, 2025
IL10 agonists and methods of use thereof
REGENERON PHARMA0 citations57
US11673930B2Jun 13, 2023
IL10 agonists and methods of use thereof
REGENERON PHARMA0 citations57
US10532096B2Jan 14, 2020
Methods and compositions comprising a combination of a VEGF antagonist and an anti-CTLA-4 antibody
REGENERON PHARMA0 citations52